Abrogation of local cancer recurrence after radiofrequency ablation by dendritic cell-based hyperthermic tumor vaccine
/in Dendritic Cells, Hyperthermia, International Publications /von 2009-09-22 / Mol. Ther. 2009 Dec;17(12):2049-57Enhanced T-cell activation by immature dendritic cells loaded with HSP70-expressing heat-killed melanoma cells
/in Dendritic Cells, Hyperthermia, International Publications /von 2009-09-15 / Exp. Dermatol. 2010 Feb;19(2):108-16Lung cancer-associated tumor antigens and the present status of immunotherapy against non-small-cell lung cancer
/in International Publications, NSCLC /von 2009-09-13 / Gen Thorac Cardiovasc Surg 2009 Sep;57(9):449-57Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL
/in Dendritic Cells, International Publications /von 2009-09-08 / Mol. Ther. 2010 Feb;18(2):264-74Polarization of human monocyte-derived dendritic cells to DC1 by in vitro stimulation with Newcastle Disease Virus
/in Dendritic Cells, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2009-09-01 / J BUON 2009 Sep;14 Suppl 1:S111-22Immunogenicity of 56 degrees C and UVC-treated prostate cancer is associated with release of HSP70 and HMGB1 from necrotic cells
/in Dendritic Cells, Hyperthermia, International Publications /von 2009-09-01 / Prostate 2009 Sep;69(12):1343-52Massive expansion of regulatory T-cells following interleukin 2 treatment during a phase I-II dendritic cell-based immunotherapy of metastatic renal cancer
/in Dendritic Cells, Hypernephroma, International Publications /von 2009-09-01 / Int. J. Oncol. 2009 Sep;35(3):569-81Brain tumor immunotherapy with type-1 polarizing strategies
/in Glioblastoma, International Publications /von 2009-09-01 / Ann. N. Y. Acad. Sci. 2009 Sep;1174:18-23Combining conventional therapies with intratumoral injection of autologous dendritic cells and activated T cells to treat patients with advanced cancers
/in Dendritic Cells, International Publications /von 2009-09-01 / Ann. N. Y. Acad. Sci. 2009 Sep;1174:41-50
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution